Abstract
There are few therapeutic options for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have recurrent disease after initial matched sibling hematopoietic stem cell transplantation. While a second hematopoietic stem cell transplant (HSCT) from a haploidentical donor offers the conceptual possibility of greater graft versus leukemia effect, there is minimal literature to describe the efficacy of this approach in recurrent pediatric T-ALL. We present the case of a now 9-year-old female in whom second haploidentical HSCT, followed by successive donor lymphocyte infusions in response to minimal residual disease reemergence, has led to 3+ years of ongoing disease control without graft versus host disease and excellent quality of life.
Original language | English (US) |
---|---|
Pages (from-to) | 1279-1282 |
Number of pages | 4 |
Journal | Pediatric Blood and Cancer |
Volume | 63 |
Issue number | 7 |
DOIs | |
State | Published - Jul 1 2016 |
Keywords
- Donor lymphocyte infusion
- Haploidentical bone marrow transplant
- Relapse
- T-cell acute lymphoblastic leukemia
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology